EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient

Joaquim Viñes iD, Sabina Herrera, Andrea Vergara iD, Ignasi Roca iD, Jordi Vila iD, Tommaso Francesco Aiello iD, José Antonio Martínez, Ana Del Río, Carlos Lopera, Carolina Garcia-Vidal, Climent Casals-Pascual, Àlex Soriano und 1 weitere

Microbiology Spectrum · 04.03.2025 · 13 (3)

DOI: 10.1128/spectrum.01928-24 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Microbiology Spectrum, erschienen am 04.03.2025. Verfasst von Joaquim Viñes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Microbiologia i Parasitologia-CDB, Hospital Clínic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Anti-Bacterial Agents, Cephalosporins. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación (MCIN), Government of Catalonia | Departament d'Universitats, Recerca i Societat de la Informació (DURSI), Generalitat de Catalunya (Government of Catalonia).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudomonas aeruginosa is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing P. aeruginosa has further complicated the management of nosocomial infections, limiting therapeutic options. Cefiderocol has recently emerged as a promising antipseudomonal agent, using the bacterial iron transport system to gain entry into the cell; however, there have been reports of P. aeruginosa resistant to cefiderocol. We describe the in vivo cefiderocol resistance progression of four consecutive P. aeruginosa isolates from one patient with T-cell acute lymphoblastic leukemia. Analysis of potential genes involved in cefiderocol transport resulted in three genes mutated in two resistant isolates. One isolate presented a S116F substitution in PiuC, and the other presented a deletion of 29 amino acids in the signal peptide of PiuA and a STOP substitution in PirA, resulting in the deletion of a piece of the channel. These mutations increased 24- and 64-folds the cefiderocol minimum inhibitory concentration, respectively. The mutations in the aforementioned genes may directly impact siderophore internalization, thereby contributing to an elevation in the MIC of the antibiotic. IMPORTANCE Carbapenem-resistant Pseudomonas aeruginosa poses a significant challenge due to its broad antibiotic resistance. Cefiderocol is a novel antibiotic aimed at combating infections caused by such organisms. However, if these pathogens develop resistance to this new drug, it hinders treatment efficacy and options. Therefore, it is crucial to identify and describe mutations in the genes involved in the uptake of cefiderocol to find better treatment strategies for patients infected with multidrug-resistant P. aeruginosa .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial AgentsCephalosporinsBacterial ProteinsHumansbeta-LactamasesCefiderocolMicrobial Sensitivity TestsMutationMaleDrug Resistance, BacterialPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Stichwörter der Autor:innen

Oxford NanoporePirAPiuAPiuCPseudomonas aeruginosacarbapenem-resistantcefiderocolleukemia

Substanzen

Anti-Bacterial Agentsbeta-LactamasesCefiderocolCephalosporinsBacterial Proteins

Autor:innen und Institutionen

  • Servei de Microbiologia i Parasitologia-CDB, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Institut de Salut Global (ISGlobal), Barcelona, Spain.
  • Servei Veterinari de Genètica Molecular (SVGM), Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Departament de Malalties Infeccioses, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
  • CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.

ORCID-Profile: Joaquim Viñes, Andrea Vergara, Ignasi Roca, Jordi Vila, Tommaso Francesco Aiello

Förderung

  • Ministerio de Ciencia e Innovación (MCIN)
  • Government of Catalonia | Departament d'Universitats, Recerca i Societat de la Informació (DURSI)
  • Generalitat de Catalunya (Government of Catalonia)
  • Ministerio de Sanidad, Consumo y Bienestar (MSCBS)
  • Ministerio de Universidades (MU)

Zitieren

APA

Viñes, J., Herrera, S., Vergara, A., Roca, I., Vila, J., Aiello, T. F., Martínez, J. A., Del Río, A., Lopera, C., Garcia-Vidal, C., Casals-Pascual, C., Soriano, À., & Pitart, C. (2025). Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient. Microbiology Spectrum, 13(3). https://doi.org/10.1128/spectrum.01928-24

Vancouver

Viñes J, Herrera S, Vergara A, Roca I, Vila J, Aiello TF, et al. Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient. Microbiology Spectrum. 2025;13(3). doi:10.1128/spectrum.01928-24

BibTeX
@article{Vies2025,
  author = {Viñes, Joaquim and Herrera, Sabina and Vergara, Andrea and Roca, Ignasi and Vila, Jordi and Aiello, Tommaso Francesco and Martínez, José Antonio and Del Río, Ana and Lopera, Carlos and Garcia-Vidal, Carolina and Casals-Pascual, Climent and Soriano, Àlex and Pitart, Cristina},
  title = {Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {3},
  doi = {10.1128/spectrum.01928-24}
}
Kostenlos starten →